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A previously uncharacterized gene, DBC2 (deleted in breast cancer),
was cloned from a homozygously deleted region at human chro-
mosome 8p21. DBC2 contains a highly conserved RAS domain and
two putative protein interacting domains. Our analyses indicate
that DBC2 is the best candidate tumor suppressor gene from this
region. It lies within the epicenter of the deletions and is homozy-
gously deleted in 3.5% (7200) of breast tumors. Mutation analysis
of DBC2 led to discovery of two instances of somatic missense
mutations in breast tumor specimens, whereas no missense mu-
tations were found in other candidates from the region. Unlike
other genes in the region, expression of DBC2 is often extinguished
in breast cancer cells or tissues. Moreover, our functional analysis
revealed that DBC2 expression in breast cancer cells lacking DBC2
transcripts causes growth inhibition. By contrast, expression of a
somatic mutant discovered in a breast cancer specimen does not
suppress the growth of breast cancer cells.
In the course of carcinogenesis, cancer cells acquire a numberof genetic changes, many of which may have no effect on
cellular function. There are, however, critical genetic alterations
that affect two classes of genes: oncogenes that are activated or
altered in function and tumor suppressor genes that are down-
regulated or ablated in cancer cells. Discovery and analysis of
these genetic changes have contributed to a better understanding
of the molecular basis of cancer development. Studies on BRCA1
and -2 tumor suppressor genes have provided useful information
for understanding familial breast cancer (1). Other tumor sup-
pressor genes are involved in sporadic breast cancer, including
PTEN and p53 (2, 3). However, it is likely that many, if not most,
tumor suppressor genes responsible for sporadic breast cancer
remain to be discovered. Representational difference analysis
(RDA) is one tool that has been shown to be effective in the hunt
for tumor suppressor genes (3, 4). We have analyzed a few breast
cancer biopsies by RDA and isolated a number of deletion
probes. An RDA probe detecting homozygous deletion was
mapped to human chromosome 8p21, and we find this region to
be deleted in other breast cancer specimens as well. We have
mapped this region, cloned new genes residing therein, and have
found somatic mutations in cancer cells for one of the genes from
this locus.
Materials and Methods
Materials. Breast tumor specimens were procured from a variety
of sources. Aneuploid and diploid nuclei from breast tumor
specimens were prepared by fluorescence-activated sorting by
using an Elite EPS (Beckman Coulter). DNA from the sorted
nuclei was immortalized by making DpnII and BfaI representa-
tions, by using methods described elsewhere (5). Cell lines were
purchased from American Type Culture Collection or are from
our permanent collection inherited from Jorgen Fogh (Memo-
rial Sloan–Kettering Cancer Center). Chemicals and buffers
were obtained from Sigma unless otherwise noted. Enzymes
were obtained from New England Biolabs except TaqDNA
Polymerase (AmpliTaq), from Perkin–Elmer. All enzymatic
reactions were performed with buffers recommended by the
supplier.
Deletion Analysis. Deletion mapping was performed by quantita-
tive PCR (Q-PCR) with the ABI Prism 7700 Sequence Detector
(6). The Q-PCR was carried out in three stages: 50°C for 2 min,
95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for
1 min. DNA markers from 8p21 and other chromosomes were
used for Q-PCR. DNA markers were derived from the original
RDA probe WD31; from sequence tag sites WI-14743, WI-
15206, and WI-16696; from genes we discovered [deleted in breast
cancer 1 (DBC1) (GenBank accession no. AF293335) and deleted
in breast cancer 2 (DBC2) (accession no. AY009093)]; and from
known genes from this region, including EGR3 (accession no.
NM004430), tumor necrosis factor receptor super family 10B
(TNFRSF10A) (accession no. AF014794), TNFRSF10B (acces-
sion no. AC007868), and KIAA0273 (accession no. NM014759).
Additionally, DNA probe ER48 was a subcloned fragment from
a genomic clone from human chromosome 3p14, and WB23 was
a cloned fragment from human chromosome 21p.
The protocols for RDA are described elsewhere (4). All
oligonucleotides were synthesized by Operon Technologies
(Alameda, CA), except that Taqman probes for Q-PCR were
synthesized by Perkin–Elmer with 6-carboxyfluorescein at the 5
end and 6-carboxy-tetramethyl-rhodamine at the 3 end.
Gene Cloning. Gene discovery methods included exon trapping
(7), rapid isolation of cDNA by hybridization (8), cDNA library
screening, and sequence determination of genomic clones fol-
lowed by database searches. RNA ligase-mediated amplification
of cDNA ends (RLM-RACE) was performed by using the First
Choice RLM-RACE kit (Ambion, Austin, TX) (9). Computa-
tional analyses of the fragments were performed by BASIC LOCAL
ALIGNMENT SEARCH TOOL (BLAST), GCG Wisconsin Package, and
a PFAM HMM search (10, 11).
Mutation Analysis. Mutational analyses were performed by a
protein truncation test (PTT), denatured HPLC (DHPLC), and
single-strand conformation polymorphism (SSCP). For PTT, the
entire ORF of TNFRSF10B was amplified with primers,
TAATACGACTCACTATAGGGAGCCACCATGGAACAA-
CGGGGACAG and AATTGTGGCACTTTCCTACTGACT.
The PTT procedure is described elsewhere (12). WAVE Nucleic
Acid Fragment Analysis System (Transgenomic, Omaha, NE)
was used for DHPLC (13). The target fragments were amplified
by PCR with the GeneAmp PCR System 9600 (Perkin–Elmer).
Control fragments were generated by PCR from normal human
Abbreviations: DHPLC, denatured HPLC; HD, homozygous deletion; Q-PCR, quantitative
PCR; SSCP, single-strand conformation polymorphisms; RDA, representational difference
analysis.
Data deposition: The sequences reported in this paper have been deposited in the GenBank
database [accession nos. AY009093 (human DBC2), AF293335 (human DBC1), and
AF420001 (mouse DBC2)].
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DNA. The samples and control fragments were mixed, dena-
tured, reannealed to generate heteroduplexes, and then analyzed
by DHPLC. The samples with different peak patterns were
sequenced. Protocols for SSCP are described elsewhere (14).
The primer sequences for Q-PCR, DHPLC, and SSCP used in
this study will be provided on request.
Expression Analysis. Expression analyses were mainly done by
RT-PCR. Cytoplasmic RNA was extracted from cultured cells,
and total RNA was extracted from tissue samples with guani-
dinium thiocyanate followed by centrifugation in cesium chloride
solutions. The protocols are described elsewhere (15). RNA of
normal tissues was either purchased from BD Biosciences (Palo
Alto, CA) or extracted from surgical specimens. Avian myelo-
blastosis virus reverse transcriptase purchased from Boehringer
Mannheim was used to synthesize cDNA with oligo-dT primers.
PCR was then performed with AmpliTaq. The 50-l PCR
reaction mixture contains 1 l of the cDNA, 200 M of each
dNTP, 1 M of each primer, 2 units of AmpliTaq, and 1
AmpliTaq buffer. After initial denaturation at 94°C for 10 min,
30 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 3 min
were performed. The primer sequences used in this analysis
were: AACATGGAGGCCCTGTGCCAGCAGAA and
ACTCGCAGCTCCTGCATCTCT (DBC1); ACCATGTGG-
TACCCAGAAATC and TTAGACAACAGCAGCAGGGT-
CAGA (DBC2); AGTTTGACCAGAGATGC and TGAC-
CAAGGCTGAATAAATCCC (TNFRSF10A); CTTGATTGT-
GGCTGTGTTTGTT and GCCACCTTTATCTCATTGTCCA
(TNFR10B); AGCATGGAGCTGCTGTCCAC and TTAGCT-
CCCTGAACCTGGGCTACC (KIAA0273); and CCATGGAG-
GAGCCGCAGTCAGA and TTAGTCTGAGTCAGGCCCT-
TCTGT (p53).
Mutagenesis. Mutation was introduced by using the Exsite Mu-
tagenesis kit (Stratagene). Sequences of primers used for mu-
tagenesis were ATGAACCTGAGTGAGGGGGAGCT and
CAGCTCCCCCTCACTCAGGTT. The generated mutation
was confirmed by sequencing of both strands.
Gene Expression. HeLa and T-47D cells were grown in DMEM
supplemented with 15% FCS. For constitutive gene expression,
a mammalian expression vector pcDNA3.1His (Invitrogen) was
used. For inducible gene expression, an ecdysone gene expres-
sion system was used. Stable host cell lines carrying ecdysone
receptors were established by using retroviral vectors (16). The
genes of interest were cloned into pIND (Invitrogen) with an
Xpress tag at the 5 end and transfected into the host cell lines.
All constructs were verified by sequencing. The cells were
transformed with 15 g of plasmid by electroporation (field
strength  0.25 kVcm, capacitor  950 F) using Gene Pulser
II (Bio-Rad) and selected with G418 (400 gml) and Zeocin
(Invitrogen) (150 gml). Muristerone A (Invitrogen) (5 M)
was administered to induce the genes in pIND. Cell growth was
monitored by using the CyQuant Cell Proliferation Assay kit
(Molecular Probes).
Sequencing. DNA sequencing was performed with the ABI
Thermal Cycler Sequencing kit and ABI Prism 377 DNA
Sequencer (Perkin–Elmer). Both strands were sequenced unless
otherwise specified.
Results
Homozygous Deletion. RDA of breast cancer samples generated a
number of deletion probes, including WD31 from a tumor called
BBr67. Homozygous deletion (HD) of WD31 in BBr67 was
confirmed both by Southern blotting of the DNA representa-
tions made from the aneuploid nuclei of BBr67 and by the
semiquantitative PCR analysis of genomic DNA made from
these nuclei. WD31 was mapped to 8p21 by radiation hybrid
panels and genomic library screening, and the locus was scru-
tinized further. We constructed a contig of genomic clones and
applied positional cloning methods, described in Materials and
Methods. We discovered two previously uncharacterized
genes and identified four known genes extending outward from
WD31: DBC1, DBC2, TNFRSF10A, TNFRSF10B, EGR3, and
KIAA0273. These genes were mapped by us, and our mapping
order was confirmed by comparison to the human genome
sequence (www.ncbi.nlm.nih.gov) (Fig. 1).
Deletion Analysis. These genes, as well as nearby sequence tag
sites, were then used for deletion analysis. Aneuploid and diploid
nuclei from breast cancer were sorted and analyzed to determine
deletion frequency and the deletion epicenter. Although aneu-
ploid nuclei will be enriched for tumor cells, and diploid nuclei
will be enriched for normal stroma, each fraction will be
contaminated to varying extents with each other. Real-time PCR
or Q-PCR was used to analyze genetic loss for markers in the
region. Even in the presence of low levels of contamination, we
can detect a homozygous deletion as a cycle difference between
aneuploid and diploid samples (Fig. 2). We used multiple control
markers for normalization, from chromosome 8 and other
chromosomes. For example, we used ER48 and WB23 (from
other chromosomes) to standardize the DNA amount and
markers on the short arm of chromosome 8 to control for
chromosome 8 copy number. In all cases tested, Q-PCR results
were confirmed by Southern blotting of representations made
from diploid and aneuploid nuclei (Fig. 2). The deletion map-
ping using 200 breast tumors revealed that the deletion fre-
quency was 3.5%, and the deletion epicenter lay around a DNA
marker WI-16696 that was surrounded by two genes. WI-16696
is contained in the intron 7 of DBC2 and located within 1 kb of
the 3 end of TNFRSF10B. On the basis of the transcription and
deletion mapping (see Fig. 1), these two genes resided at the
deletion epicenter, and hence we studied them further.
Fig. 1. Deletion map of 8p21. The vertical lines indicate the localization of
sequence tag sites and genes used for deletion mapping, all of which were
tested against 200 tumor samples. Genes are represented by a horizontal line
with an arrowhead. The STSs are listed above the line, and the lines with a
square indicate probes derived from the genes. The arrow with double heads
indicates approximately 300 kb. Horizontal lines in the lower half represent
deletions found in the tumor samples (named, Left). The DBC2 probe and
WI-16696 demonstrated the highest deletion frequency. Both DBC2 and
TNFRSF10B genes are overlapping with different orientations and deleted in
all tumor specimens.
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Mutation Analysis. We began our study with TNFRSF10B, which
encodes the Trail2 receptor for TNF, because mutations in the
death domain of TNFRSF10B in nonsmall cell lung cancer had
been previously reported (17). Mutation analysis of the entire
ORF of TNFRSF10B was performed on 60 cancer cell lines by
both protein truncation test and DHPLC followed by sequencing
of variants, but no frameshift, missense, or nonsense mutations
were found (see Table 1).
The coding region of DBC2 was also screened for mutations
by DHPLC and SSCP, and variants further studied by sequenc-
ing, revealing two missense mutations in the BTBPOZ (broad-
complextramtrackbric-a-bracpoxviruszinc finger) domain,
found in lung and breast cancer cell lines. Ninety-five primary
tumors and matched normals were then screened by either
DHPLC or SSCP for mutations in either of these two genes (see
Table 1). Samples showing variants in retention time (DHPLC)
or mobility shifts (SSCP) were sequenced, and tumors were
compared with matched normals (Fig. 3). No frameshift, mis-
sense, or nonsense mutations were found in TNFRSF10B. How-
ever, two missense mutations within DBC2 were again discov-
ered within tumors but not in matched normals, indicating that
somatic mutations had occurred. One of these mutations, caus-
ing Asp-2993Asn, was in the BTBPOZ domain and was
confirmed by an independent PCR amplification and sequencing
reaction. This mutation was used for functional studies described
below. In total, from cell lines and tumors, four missense
mutations in the coding region of DBC2 were found (see Fig. 4),
but no significant mutations were found in TNFRSF10B.
Computational Analysis. To the best of our knowledge, DBC2 is a
previously unreported gene. The cDNA for DBC2 was obtained
by cDNA library screening and completeness confirmed by using
RNA ligase-mediated amplification of cDNA ends. PFAM anal-
ysis of our sequence revealed DBC2 contained a RAS domain at
its 5 end and two BTBPOZ domains. The RAS domain of
DBC2 has high homology to that of small GTP-binding proteins
(G proteins), including the sites for binding to, and hydrolysis of,
GTP (Fig. 4). However, DBC2 is distinct from the typical RAS
family members. First, DBC2 has additional functional domains.
Second, DBC2 lacks the C-terminal lipid-binding sites that
anchor the typical family member to membranes. BLAST analysis
revealed two human genes with a similar RAS-BTBPOZ
structure: KIAA0740 and KIAA0878 (accession nos. AB018283
and AB020685, respectively), the first one with high homology,
and several genes in other organisms including Mus musculus
(accession nos. AF420001, AK005770, and AK006650), Dro-
Fig. 2. Deletion analysis of tumor samples. (A) Real-time PCR analysis of a
breast tumor sample CHTN41 is demonstrated. The abscissa is cycle number of
PCR and the ordinate is quantity of PCR products. The control primer set in this
figure is WB23 from chromosome 22. ‘‘D’’ and ‘‘A’’ represent DNA from diploid
and aneuploid fractions, respectively. The amplification curve from aneuloid
DNA with WD31 primer set has a several cycle difference from the others,
indicating deletion of WD31 in this tumor. (B) Southern blot analysis of DpnII
representation with WD31 probe is shown. Each lane contains 5 g of DpnII
restriction fragments. Lanes 1 and 2 are DNA from a tumor and a matched
normal (CHTN40), respectively, showing no deletion. Lanes 3 and 4 contain
DNA from a tumor and a matched normal pair (CHTN41), showing deletion.
ER48 is a control probe derived from chromosome 3. Lane 3 has a very faint
band for DBC2, whereas the control probe exhibits the same intensity for
tumor and normal samples, representing homozygous deletion. Contamina-
tion of normal stromal cells is considered to contribute the faint band.
Table 1. Frequency of codon-altering point mutations found in
three genes in the deleted region
Gene Materials
Protein
truncation
test SSCP DHPLC
TNFRSF10B Cell lines 060 NA 060
Primary tumor NA 090 NA
DBC2 Cell lines 060 260 265
Primary tumor NA 265 NA
DBC1 Cell lines 060 NA 060
Primary tumor NA NA NA
NA, not applicable.
Fig. 3. Electrophoretogram of sequencing analysis. ‘‘D’’ and ‘‘A’’ designate
sequencing results of DNA from diploid and aneuploid nuclei of tumor sample
CHTN56, respectively. Arrow indicates position of somatic mutation.
Hamaguchi et al. PNAS  October 15, 2002  vol. 99  no. 21  13649
G
EN
ET
IC
S
sophila melanogaster (accession no. AF217287), and Dictyosteli-
um discoideum (accession no. AF310886) (Fig. 4).
The BTBPOZ domain functions as a specific protein–protein
interaction motif in known proteins (18). It is evolutionarily
conserved and found primarily at the N terminus of zinc-finger
transcription factors. Many BTBPOZ proteins are transcrip-
tional regulators that mediate gene expression through the
control of chromatin conformation; examples are BACH1 and -2,
PATZ, and PLZF, all of which interact with other proteins
through their BTBPOZ domains. Unlike these proteins, DBC2
has two BTBPOZ domains located at the C terminus.
Expression Analysis. To gain more support for the hypothesis that
loss of DBC2 may play a role in breast cancer, and possibly other
cancers, we examined its expression pattern in a variety of
neoplastic and normal cells and tissues. We used RT-PCR to
monitor the presence of DBC2 mRNA, as well as two other genes
from its locus, DBC1 and TNFRSF10B. In a subset of cases, we
tested our results by RNA blotting, and in all those cases, our
RT-PCR results were confirmed. In Fig. 5, we show some
representative data, illustrating the lack of expression of DBC2
in T-47D, a breast cancer cell line. Our data are summarized in
Table 2. For neoplastic cells and tissues, we drew on our
collection of cultured tumor cell lines and frozen tissue biopsies
from various sources, and for normal, we used multiple normal
tissue samples, including breast and placenta (Materials and
Methods). We find that all three genes are expressed ubiquitously
in all normal sources. However, DBC2 expression is extinguished
in about half of breast and lung cancer specimens, but not in
colon or other cancers we examined. In contrast, neither
TNFRSF10B nor DBC1 expression is substantially extinguished
in cancers from any source.
Functional Analysis of DBC2. To study the function of DBC2, we
expressed wild-type and mutated DBC2 in cancer cell lines. We
Fig. 4. Structure of DBC2. (A) The intron–exon structure of DBC2 (GenBank
accession no. AF315385) and predicted functional domains of DBC2 are
shown. The rectangles with a number represent exons. The shaded area
indicates coding sequences. Based on deduced amino acid sequence, molec-
ular mass of the predicted DBC2 product is 83 kDa. The asterisks denote
missense mutations we have discovered. There were three in exon 5: T to G
(7762), causing Tyr-2843Asp in a lung cancer cell line (SK-Mes-1), G to A
(7807), causing Asp-2993Asn in a primary breast tumor (CHTN56), and A to C
(8015), causing Asp-3683Ala in a breast cancer cell line (BT483); and one in
exon 9: C to A (16389), causing Phe-6473Thr in a primary breast tumor (P-1).
(B) Phylogenic tree demonstrating overall homology between DBC2 and
human RAS family members is shown. A table of the pairwise distances
between the genes was prepared by GCG Wisconsin Package, and a phylo-
gram was then created from the table by using the neighbor-joining method.
The length of a horizontal line is proportional to estimated divergence along
each branch. Accession numbers of the genes used for this analysis are: RRAS1
(P10301); RRAS2 (P17082); RIT (AAB42213); RAN (P17080); RAD (P55042); RIN
(AAB42214); RAB3A (P20336); GEM (P55040); RHEB (Q15382); RRAS2
(O14807); RHO A (P06749); H-RAS (P01112); RAP A (P10113); RAC1 (P15154);
G25K (P25763); and RAL A (P11233). (C) RAS-BTB proteins from different
organisms are compared. Accession numbers of the genes are listed after the
designation of the organism: Hs, Homo sapiens; Mm, M. musculus; Dm, D.
melanogaster; and Dd, Dictyostelium discoideum.
Fig. 5. RT-PCR analysis of tumor specimens. (A) RT-PCR products from mRNA
of T-47D with five primer sets. Lanes 1–5 contain RT-PCR products with primers
of DBC1, DBC2, KIAA0273, TNFRSF10A, and p53, respectively. Transcripts of all
genes but DBC2 were detected in T-47D. (B) RT-PCR products with the DBC2
primer pair. Lanes 6–11 contain RT-PCR products from NCI-H82, Saos-2, SK-
BR-3, SW 982, T-47D, and T84, respectively. DBC2 expression was observed in
NCI-H82, Saos-2, SK-BR-3, and SW 982 but not in T-47D or T84.
Table 2. RT-PCR analysis of DBC2, TNFRSF10B, and DBC1
Tissue of
origin DBC2 TNFRSF10B DBC1
Neoplasm Breast 42% (819) 89% (1719) 84% (1619)
Lung 50% (714) 93% (1314) 86% (1214)
Colon 83% (1012) 100% (1212) 92% (1112)
Other 91% (1011) 82% (911) 100% (1111)
Normal Breast 100% (1313) 100% (88) 100% (88)
Lung 100% (11) 100% (11) 100% (11)
Placenta 100% (22) 100% (22) 100% (22)
Brain 100% (33) 100% (33) 100% (33)
Total 100% (1919) 100% (1414) 100% (1414)
The percentage of the specimens with detectable expression of the indi-
cated gene is listed. The denominator in parentheses indicates the number of
specimens tested and the numerator, the number of positives. Neoplasm
specimens are cell lines; normal specimens are tissue.
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generated the G-to-A mutation at nucleotide position 7807
(Asp-2993Asn), which was discovered in breast tumor speci-
men CHTN56.
First, wild-type DBC2 and the mutant were cloned into
pcDNA3.1His for constitutive expression. Use of this vector
results in expression of an epitope-tagged product. Wild-type
and mutant DBC2 vectors were introduced into HeLa cells that
express endogenous DBC2. Expression of exogenous genes was
verified by Western blot analysis, and neither affected the growth
of the HeLa cells. Next we tested T-47D, the breast cancer cell
line described above and in Fig. 5. T-47D cells transformed with
wild-type DBC2 were difficult to obtain, and even when trans-
formants were cloned, expression of DBC2 could not be
detected.
We therefore used an ecdysone inducible gene expression
system to analyze effects of DBC2 expression in T-47D, using
pIND. T-47D stopped proliferating 12 h after induction of
wild-type DBC2. Growth suppression lasted for about 36 h. In
contrast, induced expression of mutant DBC2 (Asp-2993Asn)
did not suppress growth (Fig. 6). Induced expression was con-
firmed by RNA blot analysis (see for example Fig. 7).
Discussion
HDs have been a good starting point for the discovery of tumor
suppressor genes. Many researchers have tried to detect these
HDs by comparing tumors with corresponding normal tissues
(19). Arbitrarily primed PCR (APPCR) has been successfully
used in some cases, but it can examine only a small portion of
genome, because certain combinations of primer will amplify
limited numbers of fragments. Furthermore, cloning the differ-
ences detected by APPCR is often difficult. Comparative
genomic hybridization can screen the entire genome and is a
powerful tool for detecting loss of heterozygosity (LOH) and
amplification, but its relatively low resolution neither allows HD
detection nor provides much help in localizing regions. DNA
microarray technology may be sufficiently sensitive to detect HD
(20), but the true utility of this technique for identifying tumor
suppressor genes remains to be established. RDA is currently an
effective method to clone HD probes (3, 4), although it too has
certain limitations. These limitations include the need for fur-
ther analysis to distinguish HD from LOH, and that HD probes
found by RDA are generally from large deletions. Hence,
detailed deletion mapping is required to define the targeted
genetic regions. The first problem is not insurmountable. RDA
favors detection of HD over LOH, and RDA probes can be
further analyzed to distinguish between these events. The second
problem is likely to ease as the transcription map of humans
becomes better defined.
The initial discovery of an RDA HD probe has resulted in the
definition of a region on chromosome 8p that is frequently
deleted in breast cancer. The HD region at 8p21, as illustrated
here, contains at least six genes. In this report, we have focused
on the analysis of two genes, TNFRSF10B and DBC2, because
they reside in the deletion epicenter. There are four other genes
that map to this region and are deleted in at least one tumor, but
they are less frequently deleted. One of these, DBC1, was
discovered by us; although it has a long ORF, it shows no
homology to any known genes. It is expressed ubiquitously, but
we found no point mutations within its coding domains (see
Table 1). KIAA0273, found on the border of the region, corre-
sponds to a spliced EST with no known function, and we do not
find it expressed in normal breast tissue (data not presented). It
was not studied further. EGR3 is a transcription factor impli-
cated in the development of neuromuscular junctions. Knock-
out mice are not reported to show increased tumorigenicity, and
it was not studied further (21). TNFRSF10A encodes a decoy
receptor for TNF, and we would therefore not suspect it as a
tumor suppressor.
In contrast to EGR3, DBC1, KIAA0273, and TNFRSF10A,
TNFRSF10B looked like a reasonable tumor suppressor candi-
date. TNFRSF10B encodes the Trail2 receptor for TNF, and
mutations in the death domain of TNFRSF10B in nonsmall cell
lung cancer had been previously reported. Overexpression of
TNFRSF10B induces apoptosis of tumor cells in a p53-dependent
manner (22). However, we did not detect mutations in
TNFRSF10B in breast cancers, implying either that TNFRSF10B
is not the tumor suppressor gene involved in breast cancer, or
that its inactivation mechanism is not frequently caused by
mutations in coding regions. We believe the latter to be unlikely,
but TNFRSF10B cannot be completely ruled out as a candidate
tumor suppressor for breast cancer.
Fig. 6. Effects of gene induction on the growth of T47D. T-47D cells with
various constructs were treated with 5 M Muristerone A. Percent increase of
the cell count from 12 h after induction is shown. Expression of wild-type DBC2
inhibits cell growth of T47D between 12 and 48 h after gene induction,
whereas mutant DBC2 and the empty vector have no influence on T47D
proliferation.
Fig. 7. RNA blot analysis of T47D with inducible DBC2. T-47D cells with
inducible DBC2 were treated with 5 M of Muristerone A. DBC2 expression
was examined at various time points after induction. The DBC2 transcript was
detected only after induction. The control is  actin.
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The discovery of missense mutations in the coding region of
DBC2, residing at the epicenter of deletion, makes DBC2 the
lead candidate for a tumor suppressor gene within the deletion
locus at 8p21. Three of four mutations we discovered are located
in the BTBPOZ domain and create radical amino acid substi-
tutions likely to change protein function. In fact, functional
analysis revealed that DBC2 suppresses growth of a breast cancer
cell line T-47D, but a mutant (Asp-2993Asn) does not. If we
sum all deletions and point mutations, we find genetic alteration
of DBC2 in nearly 10% of breast cancer samples. Furthermore,
our work indicates that, whereas DBC2, TNFRSF10B, and DBC1
are all expressed in normal breast tissue, only expression of
DBC2 is frequently extinguished in breast cancers (1119).
All these data suggest the involvement of DBC2 in breast
cancer, but its involvement in other cancers is not excluded. In
fact, mutation in DBC2 was found in one lung cancer cell line,
and DBC2 expression was found extinguished in lung cancers.
DBC2 expression is not suppressed in colon cancer or other
types of tumors we have tested. These findings imply that DBC2
may function as a tumor suppressor in a tissue specific manner.
A possible explanation is that DBC2 tumor suppressor function
may be circumvented by alternative biological pathways in
certain tissues. The existence of altered response to DBC2 is
supported by the observation that nearly half of breast cancer
cells express DBC2. This hypothesis will also explain resistance
of HeLa cells to growth inhibition caused by DBC2 expression.
The structure of DBC2 suggests that it encodes a signal
transduction protein. It encodes a protein with significant RAS
homology and contains known protein–protein interaction do-
mains. Its novel combination of structural domains, lack of a
membrane anchor sequence at the C terminus, and divergence
from RAS proteins with known functions suggest that its func-
tion may be distinct from other members of the superfamily.
Curiously, although DBC2 is an evolutionarily conserved pro-
tein, with homologs M. muculus and D. melanogaster, homologs
are not found in all eukaryotes and are conspicuously absent in
Caenorhabditis elegans (23) and Saccharomyces cerevisiae
(http:genome-www.stanford.eduSaccharomyces). Further
work is clearly warranted to illuminate the role of DBC2 in
normal and pathophysiology.
This research was supported by grants to M.H. from the V Foundation,
GCCARES (Glen Cove CARES, Inc.), and the Department of Defense
Breast Cancer Research Program, which is managed by the U.S. Army
Medical Research and Materiel Command (BC991222). This work was
supported by a grant to M.C.K. from the National Institutes of Health
(R01 CA27632). This work was also supported by grants to M.W. from
the National Institutes of Health and National Cancer Institute (OIG-
CA39829; 5R01-CA78544; 1R21-CA81674; 5P50-CA68425-05
SPORE); Tularik Incorporated; 1 in 9: The Long Island Breast Cancer
Action Coalition; Lillian Goldman; and the Breast Cancer Research
Foundation. M.W. is an American Cancer Society Research Professor.
1. Bishop, D. T. (1999) Ann. Oncol. 10, 113–119.
2. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. (1991) Science 253,
49–53.
3. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J.,
Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) Science 275, 1943–1947.
4. Lisitsyn, N. A., Lisitsina, N. M., Dalbagni, G., Barker, P., Sanchez, C. A.,
Gnarra, J., Linehan, W. M., Reid, B. J. & Wigler, M. H. (1995) Proc. Natl. Acad.
Sci. USA 92, 151–155.
5. Lucito, R., Nakimura, M., West, J. A., Han, Y., Chin, K., Jensen, K.,
McCombie, R., Gray, J. W. & Wigler, M. (1998) Proc. Natl. Acad. Sci. USA 95,
4487–4492.
6. Bieche, I., Olivi, M., Champeme, M. H., Vidaud, D., Lidereau, R. & Vidaud,
M. (1998) Int. J. Cancer 78, 661–666.
7. Hamaguchi, M., Sakamoto, H., Tsuruta, H., Sasaki, H., Muto, T., Sugimura, T.
& Terada, M. (1992) Proc. Natl. Acad. Sci. USA 89, 9779–9783.
8. Hamaguchi, M., O’Connor, E. A., Chen, T., Parnell, L., McCombie, R. W. &
Wigler, M. H. (1998) Proc. Natl. Acad. Sci. USA 95, 3764–3769.
9. Liu, X. & Gorovsky, M. A. (1993) Nucleic Acids Res. 21, 4954–4960.
10. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W.
& Lipman, D. J. (1997) Nucleic Acids Res. 25, 3389–3402.
11. Bateman, A., Birney, E., Durbin, R., Eddy, S. R., Howe, K. L. & Sonnhammer,
E. L. (2000) Nucleic Acids Res. 28, 263–266.
12. Den Dunnen, J. & Van Ommen, G. (1999) Hum. Mutat. 14, 95–102.
13. Wagner, T., Stoppa-Lyonnet, D., Fleischmann, E., Muhr, D., Pages, S.,
Sandberg, T., Caux, V., Moeslinger, R., Langbauer, G., Borg, A. & Oefner, P.
(1999) Genomics 62, 369–376.
14. Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K. & Sekiya, T. (1989) Proc.
Natl. Acad. Sci. USA 86, 2766–2770.
15. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual, eds. Ford, N. & Nolan, C. (Cold Spring Harbor Lab. Press,
Plainview, NY).
16. Stolarov, S., Chang, K., Reiner, A., Wigler, M. & Mittal, V. (2001) Proc. Natl.
Acad. Sci. USA 98, 13043–13048.
17. Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee,
J. H., Han, S. Y., Park, J. Y., Oh, R. R., et al. (1999) Cancer Res. 59,
5683–5686.
18. Bardwell, V. J. & Treisman, R. (1994) Genes Dev. 8, 1664–1677.
19. Gray, J. W. & Collins, C. (2000) Carcinogenesis 21, 443–452.
20. Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov,
A., Williams, C. F., Jeffrey, S. S., Botstein, D. & Brown, P. O. (1999) Nat. Genet.
23, 41–46.
21. Tourtellotte, W. G. & Milbrandt, J. (1998) Nat. Genet. 20, 87–91.
22. Takimoto, R. & El-Deiry, W. S. (2000) Oncogene 19, 1735–1743.
23. The C. elegans Sequencing Consortium (1998) Science 282, 2012–2018.
13652  www.pnas.orgcgidoi10.1073pnas.212516099 Hamaguchi et al.
